S J Kuramoto1, A S B Bohnert, C A Latkin. 1. Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, USA.
Abstract
AIMS: We empirically identified subtypes of inner-city users of heroin and cocaine based on type of drug used and route of administration. METHOD: The sample was recruited from the communities in Baltimore, MD (SHIELD study) and consisted of 1061 participants who used heroin and or cocaine in the past 6 months on a weekly basis or more. Latent class analysis (LCA) was used to identify subtypes of drug users based on type of drug and route of administration. Logistic regression was used to compare the subtypes on depressive symptoms, injection risk and drug network compositions. FINDINGS: Inner-city drug users were classified into five subtypes: three subtypes of injection drug users (IDUs) [heroin injecting (n=134; 13%), polydrug and polyroute (n=88, 8%), and heroin and cocaine injecting (n=404, 38%)], and two subtypes with low proportions of IDUs (LIDUs) [heroin snorting (n=275, 26%) and crack smoking (n=160; 14%)]. The polydrug and polyroute subtype had the highest depressive symptoms risk among all subtypes. Injection risk was lowest in the heroin injecting subtype and significantly differed from heroin and cocaine injecting subtype. The IDU subtypes also varied in the drug network compositions. The LIDU subtypes had similar depressive symptoms risk but vastly differed in the drug network compositions. CONCLUSIONS: Subgroups of inner-city cocaine and heroin users based on type and route of administration differed in their depressive symptoms, injection risk and drug network compositions. Future studies should longitudinally examine factors associated with transitioning across these subtypes to better inform prevention and treatment efforts.
AIMS: We empirically identified subtypes of inner-city users of heroin and cocaine based on type of drug used and route of administration. METHOD: The sample was recruited from the communities in Baltimore, MD (SHIELD study) and consisted of 1061 participants who used heroin and or cocaine in the past 6 months on a weekly basis or more. Latent class analysis (LCA) was used to identify subtypes of drug users based on type of drug and route of administration. Logistic regression was used to compare the subtypes on depressive symptoms, injection risk and drug network compositions. FINDINGS: Inner-city drug users were classified into five subtypes: three subtypes of injection drug users (IDUs) [heroin injecting (n=134; 13%), polydrug and polyroute (n=88, 8%), and heroin and cocaine injecting (n=404, 38%)], and two subtypes with low proportions of IDUs (LIDUs) [heroin snorting (n=275, 26%) and crack smoking (n=160; 14%)]. The polydrug and polyroute subtype had the highest depressive symptoms risk among all subtypes. Injection risk was lowest in the heroin injecting subtype and significantly differed from heroin and cocaine injecting subtype. The IDU subtypes also varied in the drug network compositions. The LIDU subtypes had similar depressive symptoms risk but vastly differed in the drug network compositions. CONCLUSIONS: Subgroups of inner-city cocaine and heroin users based on type and route of administration differed in their depressive symptoms, injection risk and drug network compositions. Future studies should longitudinally examine factors associated with transitioning across these subtypes to better inform prevention and treatment efforts.
Authors: Michael T Lynskey; Arpana Agrawal; Kathleen K Bucholz; Elliot C Nelson; Pamela A F Madden; Alexandre A Todorov; Julia D Grant; Nicholas G Martin; Andrew C Heath Journal: Twin Res Hum Genet Date: 2006-08 Impact factor: 1.587
Authors: Arpana Agrawal; Michael T Lynskey; Pamela A F Madden; Kathleen K Bucholz; Andrew C Heath Journal: Addiction Date: 2007-01 Impact factor: 6.526
Authors: Wilson M Compton; Linda B Cottler; Jacqueline L Jacobs; Arbi Ben-Abdallah; Edward L Spitznagel Journal: Am J Psychiatry Date: 2003-05 Impact factor: 18.112
Authors: Peter D Alexander; Kristina M Gicas; Alex Cheng; Donna J Lang; Ric M Procyshyn; Alexandra T Vertinsky; William J Panenka; Allen E Thornton; Alexander Rauscher; Jamie Y X Wong; Tasha Chan; Andrea A Jones; F Vila-Rodriguez; William G Honer; Alasdair M Barr Journal: Psychopharmacology (Berl) Date: 2019-06-22 Impact factor: 4.530
Authors: B Jacka; B C Bray; T L Applegate; B D L Marshall; V D Lima; K Hayashi; K DeBeck; J Raghwani; P R Harrigan; M Krajden; J S G Montaner; J Grebely Journal: J Viral Hepat Date: 2017-09-04 Impact factor: 3.728
Authors: Peter D Alexander; Kristina M Gicas; Taylor S Willi; Clara N Kim; Veronika Boyeva; Ric M Procyshyn; Geoff N Smith; Allen E Thornton; William J Panenka; Andrea A Jones; Fidel Vila-Rodriguez; Donna J Lang; G William MacEwan; William G Honer; Alasdair M Barr Journal: Psychopharmacology (Berl) Date: 2017-02-11 Impact factor: 4.530
Authors: P Truman Harrell; Brent Edward E Mancha; Silvia S Martins; Pia M Mauro; Julie H Kuo; Michael Scherer; Karen I Bolla; William W Latimer Journal: Am J Addict Date: 2014-03-15
Authors: Alexis M Roth; Richard A Armenta; Karla D Wagner; Scott C Roesch; Ricky N Bluthenthal; Jazmine Cuevas-Mota; Richard S Garfein Journal: Subst Use Misuse Date: 2014-10-14 Impact factor: 2.164
Authors: Philip A Chan; Jennifer Rose; Justine Maher; Stacey Benben; Kristen Pfeiffer; Alexi Almonte; Joanna Poceta; Catherine E Oldenburg; Sharon Parker; Brandon Dl Marshall; Mickey Lally; Kenneth Mayer; Leandro Mena; Rupa Patel; Amy S Nunn Journal: AIDS Patient Care STDS Date: 2015-09-21 Impact factor: 5.078
Authors: Philip A Chan; Joseph W Hogan; Austin Huang; Allison DeLong; Marco Salemi; Kenneth H Mayer; Rami Kantor Journal: J Acquir Immune Defic Syndr Date: 2015-12-01 Impact factor: 3.731